Sodium valproate has a prophylactic effect in migraine without aura: A triple‐blind, placebo‐controlled crossover study
The DOI matches its Crossref record.
Abstract
We included 43 patients with migraine without aura in a triple-blind, placebo- and dose-controlled, crossover study of the prophylactic effect of slow-release sodium valproate; 34 patients completed the trial. The number of days with migraine was 3.5 per 4 weeks during treatment with sodium valproate and 6.1 during placebo (p = 0.002). The severity and duration of the migraine attacks that did occur were not affected by sodium valproate when compared with placebo. Fifty percent of the patients were responders, ie, their initial migraine frequency was reduced to 50% or less during sodium valproate as compared with 18% during placebo. The number of responders increased during the trial to 65% in the last 4 weeks of the active treatment period. There were no serious side effects requiring withdrawal of patients from the study. We conclude that sodium valproate is an effective and well-tolerated prophylactic medication for migraine without aura.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Guidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
Effectiveness of high‐dose riboflavin in migraine prophylaxis A randomized controlled trial
Schoenen, J., Jacquy, J., & Lenaerts, M. (1998) · Neurology · doi:10.1212/wnl.50.2.466 · Cited by 548
Microemboli may link spreading depression, migraine aura, and patent foramen ovale
Nozari, A., Dilekoz, E., Sukhotinsky, I., Stein, T., Eikermann‐Haerter, K., Liu, C., Wang, Y., Frosch, M. P., Waeber, C., Ayata, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21871 · Cited by 318
Comorbidity of migraine and epilepsy
Ottman, R., & Lipton, R. B. (1994) · Neurology · doi:10.1212/wnl.44.11.2105 · Cited by 309
Silberstein, S. D. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2008.11.007 · Cited by 299
A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
Jackson, J. L., Cogbill, E., Santana-Davila, R., Eldredge, C., Collier, W., Gradall, A., Sehgal, N., & Kuester, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130733 · Cited by 291
Divalproex Sodium in Migraine Prophylaxis: A Dose-Controlled Study
Klapper, J., & on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group (1997) · Cephalalgia · doi:10.1046/j.1468-2982.1997.1702103.x · Cited by 280
A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis
Freitag, F. G., Collins, S. D., Carlson, H. A., Goldstein, J., Saper, J., Silberstein, S., Mathew, N., Winner, P. K., Deaton, R., & Sommerville, K. (2002) · Neurology · doi:10.1212/wnl.58.11.1652 · Cited by 274
Gender differences in bipolar disorder
Arnold, L. M. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(03)00036-4 · Cited by 272
Migraine: Preventive Treatment
Silberstein, S., & Goadsby, P. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00386.x · Cited by 259
Vandervorst, F., Van Deun, L., Van Dycke, A., Paemeleire, K., Reuter, U., Schoenen, J., & Versijpt, J. (2021) · The Journal of Headache and Pain · doi:10.1186/s10194-021-01335-2 · Cited by 121
Pharmacologic Treatment of Recurrent Pediatric Headache
Graf, W. D., & Riback, P. S. (1995) · Pediatric Annals · doi:10.3928/0090-4481-19950901-08 · Cited by 9
Metadata
- Authors
- Jensen, R., Brinck, T., & Olesen, J.
- Venue
- Neurology
- Published
- 1994-04
- Volume
- 44
- Issue
- 4
- Pages
- 647-647
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2123978981
- Cited by
- 238
- References
- 0
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.